Source: Annual Congress 2004 - Primary care: challenging pulmonary problems
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. M. G. Halpin, E. Ståhl, S. A. Jansson, B. Lundbäck, F. Andersson, S. Peterson (Exeter, United Kingdom; Lund, Stockholm, Sweden). Number needed to treat (NNT) with budesonide/formoterol to avoid one COPD exacerbation, with cost analysis of treatment. Eur Respir J 2004; 24: Suppl. 48, 3349

Member's Comments

No comment yet.

Related content which might interest you: Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Number needed to treat (NNT) to prevent one exacerbation per year with omalizumab (OMA) In children with inadequately controlled allergic (IgE-mediated) asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Preventing asthma exacerbations with budesonide/formoterol maintenance + relief: a pooled analysis Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 Number needed to treat: enigmatic results for exacerbations in COPD Source: Eur Respir J 2016; 47: 354-355 Year: 2016 Number needed to treat: enigmatic results for exacerbations in COPD Source: Eur Respir J 2016; 47: 353-354 Year: 2016 Number needed to treat: enigmatic results for exacerbations in COPD Source: Eur Respir J 2015; 45: 875-878 Year: 2015 Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004 Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Estimation of tiotropium efficacy at the COPD patients with group D Source: International Congress 2015 – Different data in COPD Year: 2015 Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001